Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications
Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of CMV is categorized into prophylaxis, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicities, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.
Cost: FreeView Offer chevron_right
- 1.25 AMA PRA Category 1 Credit(s)™
- 43% of activities take less than 30 minutes to complete
- The My Healio CME Dashboard keeps track of earned credits and saved activities
- Personalized recommendations make finding your next activity easy
- Over 50,000 of your colleagues know that earn credits is faster and easier with Healio CME
- Cutomegalovirus (CMV)
- Stem cell transplantation
- anti-CMV therapies
Upon successful completion of this educational activity, participants should be better able to:
- Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent CMV disease in transplant recipients.
- Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement in survival of transplant recipients.
- Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.
The intended audience for the activities is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.
Additional credit info
This continuing medical education activity is provided by Vindico Medical Education
This activity is supported by an educational grant from Merck & Co., Inc.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, November 24, 2020, through November 23, 2021.